Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Castle Biosciences (CSTL) announced that its Board of Directors' Compensation Committee has granted restricted stock units (RSUs) to 135 employees, covering 173,542 shares of common stock. The grants were made under the Company's 2022 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4). The RSUs have a four-year vesting schedule, with 25% vesting after the first year and the remaining balance vesting in three equal annual installments, contingent on continued employment.
Castle Biosciences (CSTL) ha annunciato che il Comitato per la Compensazione del Consiglio di Amministrazione ha assegnato unità azionarie vincolate (RSU) a 135 dipendenti, coprendo 173.542 azioni di azioni ordinarie. Le assegnazioni sono state effettuate nell'ambito del Piano di Induzione 2022 della Società, in conformità con la Regola di quotazione Nasdaq 5635(c)(4). Le RSU hanno un programma di maturazione di quattro anni, con il 25% che matura dopo il primo anno e il saldo rimanente che matura in tre rate annuali uguali, a condizione di continuare l'impiego.
Castle Biosciences (CSTL) anunció que el Comité de Compensación de su Junta Directiva ha otorgado unidades de acciones restringidas (RSU) a 135 empleados, cubriendo 173,542 acciones de acciones comunes. Las concesiones se realizaron bajo el Plan de Inducción 2022 de la Compañía, cumpliendo con la Regla de Cotización 5635(c)(4) de Nasdaq. Las RSU tienen un programa de adquisición de cuatro años, con un 25% que se adquiere después del primer año y el saldo restante adquiriéndose en tres pagos anuales iguales, condicionado a la continua permanencia en el empleo.
Castle Biosciences (CSTL)는 이사회 보상 위원회가 제한된 주식 단위(RSU)를 135명 직원에게 지급하였으며, 173,542 주의 보통주를 포함하고 있다고 발표했습니다. 이 보상은 회사의 2022년 유인 계획에 따라 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)을 준수합니다. RSU는 4년의 분할 일정이 있으며, 첫 해 후 25%가 분할되고 나머지 금액은 지속적인 고용 조건 하에 3년 동안 동일한 연간 할부로 분할됩니다.
Castle Biosciences (CSTL) a annoncé que le Comité de Rémunération de son Conseil d'Administration a accordé des unités d'actions restreintes (RSU) à 135 employés, couvrant 173,542 actions ordinaires. Les attributions ont été faites dans le cadre du Plan d'Induction 2022 de la Société, conformément à la Règle de Cotation Nasdaq 5635(c)(4). Les RSU ont un calendrier d'acquisition de quatre ans, avec 25 % d'acquisition après la première année et le solde restant acquérant en trois versements annuels égaux, sous réserve d'un emploi continu.
Castle Biosciences (CSTL) gab bekannt, dass der Vergütungsausschuss des Vorstands eingeschränkte Aktieneinheiten (RSUs) an 135 Mitarbeiter vergeben hat, die 173.542 Aktien von Stammaktien abdecken. Die Vergaben erfolgten im Rahmen des Unternehmensplans zur Induktion 2022, der der Nasdaq-Listing-Regel 5635(c)(4) entspricht. Die RSUs haben einen vierjährigen Vesting-Zeitplan, wobei 25 % nach dem ersten Jahr vesten und der verbleibende Betrag in drei gleichen jährlichen Raten vesten, abhängig von der fortgesetzten Anstellung.
- Large-scale employee stock incentive program covering 135 employees indicates strong hiring and retention efforts
- Four-year vesting schedule promotes long-term employee retention
- Potential future dilution of existing shareholders due to 173,542 new shares being issued
The RSUs will vest over four years, with
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241219028828/en/
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
How many shares were granted in Castle Biosciences' (CSTL) December 2023 RSU inducement grants?
What is the vesting schedule for CSTL's December 2023 inducement RSU grants?
Under which plan were CSTL's December 2023 RSU grants issued?
How many employees received RSU grants from Castle Biosciences (CSTL) in December 2023?
